Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vical hopes to proceed with Phase III CMV vaccine trial after positive advice from EMA

This article was originally published in Scrip

Executive Summary

Vical, a US biopharmaceutical company, looks poised to move ahead with designing Phase III trials of its CMV (cytomegalovirus) vaccine, TransVax, after receiving positive scientific advice from the European Medicines Agency. The company is looking for a commercial partner for the vaccine in major markets in the Americas, Europe and Southeast Asia.

You may also be interested in...



Early Advice Crucial For Navigating Denmark’s New Appraisal System

Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Profile: Meindert Boysen On What Companies Should Expect From NICE And The Benefits Of Hill Walking

In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

Topics

Related Companies

UsernamePublicRestriction

Register

SC012122

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel